Cart

0

Stocks

“Ambrx Holders Who Bought for Pennies See 6,700% Gain on J&J Bid”

“Longtime believers in Ambrx Biopharma Inc. are being rewarded with juicy returns as Johnson & Johnson’s buyout offer values the biotech stock at more than 6,700% of its all-time low. Johnson & Johnson agreed to acquire Ambrx for $28 per… Continue Reading…

Business

“J&J plans to split into two companies, separating consumer products and pharmaceutical businesses”

“Health-care conglomerate Johnson & Johnson announced plans Friday to split its consumer products business from its pharmaceutical and medical device operations, creating two publicly traded companies. The news sent shares higher in premarket trading. The separation will sheer off its household products… Continue Reading…